SCHEMBL6520478

SCHEMBL6520478

CC(C)(C)Nc1nc(Nc2cc(CNCCO)ccn2)cc2ccn(CCO)c(=O)c12

nearest known ligand 0.40

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SYK P43405 3/20 0.40
TYK2 P29597 4/20 0.34
PDCD1 Q15116 1/20 0.32
CD274 Q9NZQ7 1/20 0.32
GRM2 Q14416 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1159214 0.93 SYK (0.40) SYKTYK2
SCHEMBL1159578 0.90 TYK2 (0.41) SYKTYK2GRM2
SCHEMBL1159514 0.89 SYK (0.41) SYKTYK2GRM2
SCHEMBL12849048 0.89 SYK (0.40) SYKTYK2GRM2
SCHEMBL6523528 0.89 SYK (0.42) SYKTYK2GRM2
SCHEMBL1159399 0.88 SYK (0.40) SYKTYK2GRM2
SCHEMBL1159114 0.87 TYK2 (0.43) SYKTYK2GRM2
SCHEMBL1159159 0.87 SYK (0.41) SYKTYK2GRM2
SCHEMBL1158393 0.86 SYK (0.42) SYKTYK2
SCHEMBL1158671 0.85 SYK (0.38) SYKTYK2GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN SYK 1/4885TYK2 35/4885PDCD1 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.